炎症指标与膀胱癌预后的相关因素分析
Correlation between Inflammation Index and Prognosis of Bladder Cancer
DOI: 10.12677/ACM.2023.13122760, PDF,   
作者: 张志勇, 陈国俊*：青海大学附属医院，泌尿外科，青海 西宁
关键词: 炎症；肿瘤发生；膀胱癌；Inflammation； Tumorigenesis； Bladder Cancer
摘要: 一些研究调查了炎症在促进肿瘤发生和癌症进展中的作用。肿瘤以及周围的基质和炎症细胞参与了相互作用，构成了炎性肿瘤微环境。肿瘤相关的炎症组织具有高度可塑性，能够不断改变其表型和功能特征。越来越多的证据表明，慢性炎症在膀胱癌的发展中起着关键作用。在这里，我们回顾了与膀胱癌相关炎症的起源，重点关注导致肿瘤发生、生长、进展和转移的机制。我们还讨论了肿瘤相关炎症组织如何成为临床上肿瘤进展风险的诊断标志物以及未来抗癌治疗的目标。
Abstract: Several studies have investigated the role of inflammation in promoting tumorigenesis and cancer progression. The tumor and the surrounding stroma and inflammatory cells participate in the in-teraction, constituting the inflammatory tumor microenvironment. Tumor-associated inflammatory tissue is highly plastic and capable of constantly changing its phenotypic and functional character-istics. There is growing evidence that chronic inflammation plays a key role in the development of bladder cancer. Here, we review the origins of inflammation associated with bladder cancer, focus-ing on the mechanisms that lead to tumorigenesis, growth, progression, and metastasis. We also discuss how tumor-associated inflammatory tissue can be a diagnostic marker for clinically signifi-cant risk of tumor progression and a target for future anticancer therapies.
文章引用：张志勇, 陈国俊. 炎症指标与膀胱癌预后的相关因素分析[J]. 临床医学进展, 2023, 13(12): 19604-19611. https://doi.org/10.12677/ACM.2023.13122760

参考文献

[1] Wigner, P., Grębowski, R., Bijak, M., Saluk-Bijak, J. and Szemraj, J. (2021) The Interplay between Oxidative Stress, In-flammation and Angiogenesis in Bladder Cancer Development. International Journal of Molecular Sciences, 22, Article 4483. [Google Scholar] [CrossRef] [PubMed]
[2] de Andrade, C.T., Rocha, G.Z., Zamuner, M., Dos Reis, R.B. and Reis, L.O. (2022) Obesity Influence on Bladder Inflammation and Cancer: A Cystitis Model. International Journal of Clinical and Experimental Pathology, 15, 373-379.
[3] Ngabire, D. and Kim, G.D. (2017) Autophagy and Inflamma-tory Response in the Tumor Microenvironment. International Journal of Molecular Sciences, 18, Article 2016. [Google Scholar] [CrossRef] [PubMed]
[4] Porta, C., Larghi, P., Rimoldi, M., Totaro, M.G., Allavena, P., Manto-vani, A. and Sica, A. (2009) Cellular and Molecular Pathways Linking Inflammation and Cancer. Immunobiology, 214, 761-777. [Google Scholar] [CrossRef] [PubMed]
[5] Nesi, G., Nobili, S., Cai, T., Caini, S. and Santi, R. (2015) Chronic Inflammation in Urothelial Bladder Cancer. Virchows Archiv, 467, 623-633. [Google Scholar] [CrossRef] [PubMed]
[6] Kuper, H., Adami, H.O. and Trichopoulos, D. (2000) Infections as a Major Preventable Cause of Human Cancer. Journal of Internal Medicine, 248, 171-183. [Google Scholar] [CrossRef] [PubMed]
[7] Lobo, N., Afferi, L., Moschini, M., Mostafid, H., Porten, S., Psutka, S.P., Gupta, S., Smith, A.B., Williams, S.B. and Lotan, Y. (2022) Epidemiology, Screening, and Prevention of Bladder Cancer. European Urology Oncology, 5, 628-639. [Google Scholar] [CrossRef] [PubMed]
[8] Jubber, I., Ong, S., Bukavina, L., Black, P.C., Compérat, E., Kamat, A.M., Kiemeney, L., Lawrentschuk, N., Lerner, S.P., Meeks, J.J., Moch, H., Necchi, A., Panebianco, V., Sridhar, S.S., Znaor, A., Catto, J.W.F. and Cumberbatch, M.G. (2023) Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. European Urology, 84, 176-190. [Google Scholar] [CrossRef] [PubMed]
[9] Hannan, T.J., Mysorekar, I.U., Hung, C.S., Isaacson-Schmid, M.L. and Hultgren, S.J. (2010) Early Severe Inflammatory Responses to Uropathogenic E. Coli Predispose to Chronic and Recurrent Urinary Tract Infection. PLOS Pathogens, 6, e1001042. [Google Scholar] [CrossRef] [PubMed]
[10] Abol-Enein, H. (2008) Infection: Is It a Cause of Bladder Cancer? Scandinavian Journal of Urology and Nephrology, 42, 79-84. [Google Scholar] [CrossRef] [PubMed]
[11] Botelho, M.C., Oliveira, P.A., Lopes, C., Correia da Costa, J.M. and Machado, J.C. (2011) Urothelial Dysplasia and Inflammation Induced by Schistosoma haematobium Total Antigen Instillation in Mice Normal Urothelium. Urologic Oncology: Seminars and Original Investigations, 29, 809-814. [Google Scholar] [CrossRef] [PubMed]
[12] Botelho, M.C., Machado, J.C. and da Costa, J.M. (2010) Schistosoma haematobium and Bladder Cancer: What Lies Beneath? Virulence, 1, 84-87. [Google Scholar] [CrossRef] [PubMed]
[13] Ohshima, H., Tatemichi, M. and Sawa, T. (2003) Chemical Basis of In-flammation-Induced Carcinogenesis. Archives of Biochemistry and Biophysics, 417, 3-11. [Google Scholar] [CrossRef] 
[14] Kantor, A.F., Hartge, P., Hoover, R.N., Narayana, A.S., Sul-livan, J.W. and Fraumeni Jr., J.F. (1984) Urinary Tract Infection and Risk of Bladder Cancer. American Journal of Epi-demiology, 119, 510-515. [Google Scholar] [CrossRef] [PubMed]
[15] Jiang, X., Castelao, J.E., Groshen, S., Cortessis, V.K., Shibata, D., Conti, D.V., Yuan, J.M., Pike, M.C. and Gago-Dominguez, M. (2009) Urinary Tract Infections and Re-duced Risk of Bladder Cancer in Los Angeles. British Journal of Cancer, 100, 834-839. [Google Scholar] [CrossRef] [PubMed]
[16] Wei, L., Gravitt, P.E., Song, H., Maldonado, A.M. and Ozbun, M.A. (2009) Nitric Oxide Induces Early Viral Transcription Coincident with Increased DNA Damage and Mutation Rates in Human Papillomavirus-Infected Cells. Cancer Research, 69, 4878-4884. [Google Scholar] [CrossRef] 
[17] Guma, S., Maglantay, R., Lau, R., Wieczorek, R., Melamed, J., Deng, F.M., Zhou, M., Makarov, D., Lee, P., Pincus, M.R., et al. (2016) Papillary Urothelial Carcinoma with Squa-mous Differentiation in Association with Human Papilloma Virus: Case Report and Literature Review. American Journal of Clinical and Experimental Urology, 4, 12-16.
[18] Groah, S.L., Weitzenkamp, D.A., Lammertse, D.P., Whiteneck, G.G., Lezotte, D.C. and Hamman, R.F. (2002) Excess Risk of Bladder Cancer in Spinal cord Injury: Evidence for an Association between Indwelling Catheter Use and Bladder Cancer. Archives of Physical Medicine and Rehabilitation, 83, 346-351. [Google Scholar] [CrossRef] [PubMed]
[19] Song, J., Li, A., Qian, Y., Liu, B., Lv, L., Ye, D., Sun, X. and Mao, Y. (2022) Genetically Predicted Circulating Levels of Cytokines and the Risk of Cancer. Frontiers in Immunology, 13, Article 886144. [Google Scholar] [CrossRef] [PubMed]
[20] Song, S., Chen, H., Dou, X., Wang, K., Yan, J. and Yu, C. (2022) The Prognostic Value of before Treatment Neutrophil-to-Lymphocyte Ratio in Nasopharyngeal Carcinoma. European Archives of Oto-Rhino-Laryngology, 279, 2485-2492. [Google Scholar] [CrossRef] [PubMed]
[21] Shau, H.Y. and Kim, A. (1988) Suppression of Lymphokine-Activated Killer Induction by Neutrophils. The Journal of Immu-nology, 141, 4395-4402. [Google Scholar] [CrossRef] 
[22] Bingle, L., Brown, N.J. and Lewis, C.E. (2002) The Role of Tumour-Associated Macrophages in Tumour Progression: Implications for New Anticancer Therapies. The Journal of Pathology, 196, 254-265. [Google Scholar] [CrossRef] [PubMed]
[23] Yang, H., Kim, C., Kim, M.J., Schwendener, R.A., Alitalo, K., Heston, W., Kim, I., Kim, W.J. and Koh, G.Y. (2011) Soluble Vascular Endothelial Growth Factor Receptor-3 Suppresses Lymphan-giogenesis and Lymphatic Metastasis in Bladder Cancer. Molecular Cancer, 10, Article No. 36. [Google Scholar] [CrossRef] [PubMed]
[24] Ayari, C., LaRue, H., Hovington, H., Caron, A., Bergeron, A., Têtu, B., Fradet, V. and Fradet, Y. (2013) High Level of Mature Tumor-Infiltrating Dendritic Cells Predicts Progression to Muscle Invasion in Bladder Cancer. Human Pathology, 44, 1630-1637. [Google Scholar] [CrossRef] [PubMed]
[25] Eruslanov, E., Daurkin, I., Vieweg, J., Daaka, Y. and Kusmartsev, S. (2011) Aberrant PGE2 Metabolism in Bladder Tumor Microenvironment Promotes Immunosuppressive Phenotype of Tumor-Infiltrating Myeloid Cells. International Immunopharmacology, 11, 848-855. [Google Scholar] [CrossRef] [PubMed]
[26] Fridlender, Z.G., Sun, J., Singhal, S., Kapoor, V., Cheng, G., Suzuki, E. and Albelda, S.M. (2010) Chemotherapy Delivered after Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-Mediated Mechanisms. Molecular Therapy, 18, 1947-1959. [Google Scholar] [CrossRef] [PubMed]
[27] Winerdal, M.E., Marits, P., Winerdal, M., Hasan, M., Rosenblatt, R., Tolf, A., Selling, K., Sherif, A. and Winqvist, O. (2011) FOXP3 and Survival in Urinary Bladder Cancer. BJU International, 108, 1672-1678. [Google Scholar] [CrossRef] 
[28] Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A.A., Gnjatic, S., Bajorin, D.F., Reuter, V.E., Herr, H., Old, L.J., et al. (2007) CD8 Tumor-Infiltrating Lymphocytes Are Predictive of Survival in Muscle-Invasive Urothelial Carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 104, 3967-3972. [Google Scholar] [CrossRef] [PubMed]
[29] Chi, L.J., Lu, H.T., Li, G.L., Wang, X.M., Su, Y., Xu, W.H. and Shen, B.Z. (2010) Involvement of T Helper Type 17 and Regulatory T Cell Activity in Tumour Immunology of Bladder Carcinoma. Clinical and Experimental Immunology, 161, 480-489. [Google Scholar] [CrossRef] [PubMed]
[30] Pignot, G., Bieche, I., Vacher, S., Güet, C., Vieillefond, A., Debré, B., Lidereau, R. and Amsellem-Ouazana, D. (2009) Large-Scale Real-Time Reverse Transcription-PCR Approach of Angiogenic Pathways in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major In-dependent Prognostic Marker. European Urology, 56, 678-689. [Google Scholar] [CrossRef] [PubMed]
[31] Reis, S.T., Leite, K.R., Piovesan, L.F., Pontes-Junior, J., Viana, N.I., Abe, D.K., Crippa, A., Moura, C.M., Adonias, S.P., Srougi, M., et al. (2012) Increased Expression of MMP-9 and IL-8 Are Correlated with Poor Prognosis of Bladder Cancer. BMC Urology, 12, Article No. 18. [Google Scholar] [CrossRef] [PubMed]
[32] Lee, S.J., Park, S.S., Lee, U.S., Kim, W.J. and Moon, S.K. (2008) Signaling Pathway for TNF-α-Induced MMP-9 Expression: Mediation through p38 MAP Kinase, and Inhibition by An-ti-Cancer Molecule Magnolol in Human Urinary Bladder Cancer 5637 Cells. International Immunopharmacology, 8, 1821-1826. [Google Scholar] [CrossRef] [PubMed]
[33] Miyake, M., Lawton, A., Goodison, S., Urquidi, V., Gomes-Giacoia, E., Zhang, G., Ross, S., Kim, J. and Rosser, C.J. (2013) Chemokine (C-X-C) Ligand 1 (CXCL1) Pro-tein Expression Is Increased in Aggressive Bladder Cancers. BMC Cancer, 13, Article No. 322. [Google Scholar] [CrossRef] [PubMed]
[34] Murai, R., Itoh, Y., Kageyama, S., Nakayama, M., Ishigaki, H., Teramoto, K., Narita, M., Yoshida, T., Tomita, K., Kobayashi, K.I., et al. (2018) Prediction of Intravesical Recurrence of Non-Muscle-Invasive Bladder Cancer by Evaluation of Intratumoral Foxp3+ T Cells in the Primary Transurethral Resec-tion of Bladder Tumor Specimens. PLOS ONE, 13, e0204745. [Google Scholar] [CrossRef] [PubMed]
[35] Margulis, V., Shariat, S.F., Ashfaq, R., Thompson, M., Sagalowsky, A.I., Hsieh, J.T. and Lotan, Y. (2007) Expression of Cyclooxygenase-2 in Normal Urothelium, and Super-ficial and Advanced Transitional Cell Carcinoma of Bladder. Journal of Urology, 177, 1163-1168. [Google Scholar] [CrossRef] [PubMed]
[36] Tomlinson, D.C., Baxter, E.W., Loadman, P.M., Hull, M.A. and Knowles, M.A. (2012) FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms. PLOS ONE, 7, e38972. [Google Scholar] [CrossRef] [PubMed]
[37] Wheeler, M.A., Hausladen, D.A., Yoon, J.H. and Weiss, R.M. (2002) Prostaglandin E2 Production and Cyclooxygenase-2 Induction in Human Urinary Tract Infections and Bladder Cancer. Journal of Urology, 168, 1568-1573. [Google Scholar] [CrossRef] 
[38] Von der Emde, L., Goltz, D., Latz, S., Müller, S.C., Kristi-ansen, G., Ellinger, J. and Syring, I. (2014) Prostaglandin Receptors EP1-4 as a Potential Marker for Clinical Outcome in Urothelial Bladder Cancer. American Journal of Cancer Research, 4, 952-962.
[39] Ehsan, A., Sommer, F., Schmidt, A., Klotz, T., Koslowski, J., Niggemann, S., Jacobs, G., Engelmann, U., Addicks, K. and Bloch, W. (2002) Nitric Oxide Pathways in Human Bladder Carcinoma. The Distribution of Nitric Oxide Synthases, Soluble Guanylyl Cyclase, Cyclic Guanosine Monophosphate, and Nitrotyrosine. Cancer, 95, 2293-2301. [Google Scholar] [CrossRef] [PubMed]
[40] Gecit, I., Aslan, M., Gunes, M., Pirincci, N., Esen, R., Demir, H. and Ceylan, K. (2012) Serum Prolidase Activity, Oxidative Stress, and Nitric Oxide Levels in Patients with Bladder Cancer. Journal of Cancer Research and Clinical Oncology, 138, 739-743. [Google Scholar] [CrossRef] [PubMed]
[41] Zappavigna, S., Cossu, A.M., Grimaldi, A., Bocchetti, M., Ferra-ro, G.A., Nicoletti, G.F., Filosa, R. and Caraglia, M. (2020) Anti-Inflammatory Drugs as Anticancer Agents. Interna-tional Journal of Molecular Sciences, 21, Article 2605. [Google Scholar] [CrossRef] [PubMed]
[42] Xu, X.C. (2002) COX-2 Inhibitors in Cancer Treatment and Prevention, a Recent Development. Anti-Cancer Drugs, 13, 127-137. [Google Scholar] [CrossRef] [PubMed]
[43] Greenhough, A., Smartt, H.J., Moore, A.E., Roberts, H.R., Williams, A.C., Paraskeva, C. and Kaidi, A. (2009) The COX-2/PGE2 Pathway: Key Roles in the Hallmarks of Cancer and Adaptation to the Tumour Microenvironment. Carcinogenesis, 30, 377-386. [Google Scholar] [CrossRef] [PubMed]
[44] Dhawan, D., Craig, B.A., Cheng, L., Snyder, P.W., Mohammed, S.I., Stewart, J.C., Zheng, R., Loman, R.A., Foster, R.S. and Knapp, D.W. (2010) Effects of Short-Term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary Bladder. Molecular Cancer Therapeutics, 9, 1371-1377. [Google Scholar] [CrossRef] 
[45] Sabichi, A.L., Lee, J.J., Grossman, H.B., Liu, S., Richmond, E., Czerniak, B.A., De la Cerda, J., Eagle, C., Viner, J.L., Palmer, J.L., et al. (2011) A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer. Cancer Prevention Research, 4, 1580-1589. [Google Scholar] [CrossRef] 
[46] Rosser, C.J., Nix, J., Ferguson, L., Hernandez, L. and Wong, H.C. (2018) Phase Ib Trial of ALT-803, an IL-15 Superagonist, plus BCG for the Treatment of BCG-Naive Pa-tients with Non-Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 36, 510. [Google Scholar] [CrossRef] 
[47] Sonpavde, G., Rosser, C.J., Pan, C., Parikh, R.A., Nix, J., Gingrich, J.R., Hernandez, L., Huang, B. and Wong, H.C. (2016) Phase I Trial of ALT-801, a First-in-Class T-Cell Re-ceptor (TCR)-Interleukin (IL)-2 Fusion Molecule, plus Gemcitabine (G) for Bacillus Calmette Guerin (BCG)-Resistant Non-Muscle-Invasive Bladder Cancer (NMIBC). Journal of Clinical Oncology, 34, 451-451. [Google Scholar] [CrossRef] 

为你推荐